THERANEXUS overview

Lyon, France – 30 January 2025, 6pm CET – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces publication of its cash position as at 31 December 2024, and presents its progress report. On 31 December 2024, total available funds stood at €1.0 M, compared with €1.9 M on 30 September 2024. As stipulated in the press release of 17 December 2024 [1] , the company has since strengthened its cash position, which stood at €4.0 M as...

Lyon, France – January 23, 2025, 6:00 PM CET - Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces its financial communication agenda for 2025. Each publication will be released after Euronext market closing, unless otherwise specified. These dates are given as an indication, they are likely to be modified if necessary. Indicative calendar Events Dates Cash position as at December 31, 2024 13 February 2025 2024 Annual Results and...

Lyon, France – January 9, 2025, 6:00 PM CET - Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of its letter to shareholders. To download the newsletter, click here . This letter is also available on the Theranexus website ( link ), in the Shareholders/Financial Documents section. Theranexus invites its shareholders to register ( link ) to receive all company communications. About Theranexus Theranexus is an...

LYON, FRANCE / ACCESSWIRE / December 17, 2024 / Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases (the " Company "), today presents an update of its cash position as of 12 December 2024 and its cash flow horizon until the end of the first quarter of 2026. Total available funds on 12 December 2024 stood at €1.5 M compared with €1.9 M on 30 September 2024. The Company is expecting its position to improve by a total of €4.8 M in the short term...

Exeltis will be granted an exclusive license to market and distribute Theranexus' novel formulation TX01 for the treatment of two rare neurological diseases notably in Europe. Theranexus will be eligible to receive up-front payment, development and commercial milestones and double-digit royalties on net sales. LYON, FRANCE and MADRID, SPAIN / ACCESSWIRE / December 17, 2024 / Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, and Exeltis, a global...

Lyon, France – 17 December 2024, 6.15 pm CET – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases (the “ Company ”), today presents an update of its cash position as of 12 December 2024 and its cash flow horizon until the end of the first quarter of 2026. Total available funds on 12 December 2024 stood at €1.5 M compared with €1.9 M on 30 September 2024. The Company is expecting its position to improve by a total of €4.8 M in the short...

Exeltis will be granted an exclusive license to market and distribute Theranexus' novel formulation TX01 for the treatment of two rare neurological diseases notably in Europe. Theranexus will be eligible to receive up-front payment, development and commercial milestones and double-digit royalties on net sales. Lyon, France - Madrid, Spain – December 17, 2024, 6.00 pm CET – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, and Exeltis, a global...

A communication by BBDF and Theranexus of the promising results of the Batten-1 Phase I/II trial at the Child Neurology Society Annual Meeting in San Diego (California) Additional expanded use of miglustat providing positive signals on visual acuity in younger CLN3 patients Lyon, France – Austin, Texas, United States – November 19, 2024 – 6 PM CET – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, and the Beyond Batten Disease Foundation...